The Priority Review

Tag

FDA

70 stories · page 6 of 6

Stories

  1. Regulation

    FDA finalizes exemption for certain class II clinical toxicology test systems

    The FDA issued a final order exempting specific class II clinical toxicology test systems from premarket notification (510(k)) requirements, effective October 6, 2026. This exemption will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures required to comply with certain Federal regulations.

  2. Regulation

    FDA seeks public input to support ibogaine research

    The FDA issued a request for information (RFI) to gather comments on early-phase clinical trial design for ibogaine drug products, including dose selection, safety monitoring and ethical oversight. Stakeholders have 45 days to submit comments, with the deadline on Friday, November 20, 2026.

  3. Regulation

    FDA requests nominations for voting members of advisory committees

    The agency is seeking qualified individuals to fill scientific, technical, professional, and other voting-member positions. The notice was published October 1, 2026.

  4. Regulation

    FDA requests nominations for consumer representatives on advisory committees

    The FDA is requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. Nominations will be accepted for current vacancies and for those that will or may occur through December 31, 2026, with interest letters due by November 16, 2026.

  5. Regulation

    FDA determines ISTURISA not withdrawn from sale

    The FDA has determined that ISTURISA (osilodrostat) tablets, 10 mg, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications for osilodrostat tablets, 10 mg if all other legal and regulatory requirements are met.

  6. Regulation

    FDA classifies flushing and storage solution for vascular autografts at room temperature as class II

    The order places the device type into class II (special controls), which the FDA has determined will provide a reasonable assurance of the safety and effectiveness of the device. The FDA said the action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

  7. Approvals

    FDA approves first pediatric heart valve built to be expanded as a child grows

    Edwards Lifesciences' Autus Size-Adjustable Valve is also the first valve approved in the U.S. with polymeric leaflets instead of animal tissue.

  8. Approvals

    FDA approves Emcitate, the first treatment for MCT8 deficiency

    Egetis Therapeutics' tiratricol treats the excess blood thyroid hormone of Allan-Herndon-Dudley syndrome. The company also received a rare pediatric disease priority review voucher.

  9. Regulation

    FDA rewrites drug safety rules to say “nonclinical,” not “animal,” testing

    A direct final rule takes effect February 4, 2027, unless the agency receives significant adverse comments by December 7, 2026.

  10. Approvals

    FDA approves Fayuvi, the first gene therapy for Sanfilippo syndrome type A

    Ultragenyx's one-time AAV9 infusion received standard full approval for children with MPS IIIA, and the company received a priority review voucher.